NCT03763604Approved For Marketing不适用
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 154
研究概览
简要总结
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with hormone receptor positive metastatic breast cancer for whom there is reasonable expectation that abemaciclib may provide clinical benefit and who are suitable to receive abemaciclib.
排除标准
- 未提供
研究者
研究点 (154)
Loading locations...
相似试验
No Longer Available
不适用
Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19COVID-19NCT04603651Eli Lilly and Company
Approved For Marketing
不适用
Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerMetastatic Breast CancerNCT02792725Eli Lilly and Company
Approved For Marketing
不适用
Compassionate Use Protocol for the Treatment of Autoinflammatory SyndromesChronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)Juvenile Dermatomyositis (JDM)Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)Aicardi-Goutières Syndrome (AGS)NCT01724580Eli Lilly and Company
已完成
不适用
A Prospective Patient Registry of Patients Exposed to BedaquilinePulmonary Multi-drug Resistant TuberculosisNCT02274389Janssen Research & Development, LLC5
Approved For Marketing
不适用
International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric CancerMetastatic Gastric CancerMetastatic Adenocarcinoma of the Gastroesophageal JunctionNCT02065765Eli Lilly and Company